Internet-Administered Smoking Cessation Treatment for Overweight and Obese Smokers

• Status: Completed
• Trial end date: 2013-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This project will be a randomized clinical trial testing the efficacy of an internet-administered smoking cessation treatment for overweight and obese smokers. Research on internet-administered behavioral treatments for smoking cessation has found that compared to control treatments (e.g., self-help materials), cessation rates in internet-administered treatments are significantly higher. Research testing the applicability of these treatments to overweight and obese individuals has not yet been conducted. Given that a substantial portion of smokers are also overweight and at elevated cardiovascular risk, there is a need for directed treatment efforts for this group. The current trial proposes to be the first to test the effectiveness of internet-administered smoking cessation treatment for overweight and obese (BMI≥25) smokers. Adult participants will be randomized to receive 12 weeks of internet-administered treatment consisting of either: a) standard smoking cessation treatment with general health education, or b) standard smoking cessation treatment with cognitive behavioral therapy (CBT) for weight concerns. Participants in both conditions will receive open-label treatment with the 21 mg transdermal nicotine patch.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Collaborator: American Heart Association
• Treatments: Nicotine

Criteria

Inclusion Criteria:

• Smoking 10 or more cigarettes per day

• Regular access to the internet

• BMI>=25

Exclusion Criteria:

• Type I diabetes or Type II diabetes requiring medication

• Alcohol or drug dependence within the past year

• Females with current pregnancy or breastfeeding or intention to become pregnant within the next 12 months

• Uncontrolled hypertension

• Severe chronic obstructive pulmonary disease

• Use of an investigational drug within 30 days or current participation in another clinical trial

• Current use of tobacco products other than cigarettes or use of marijuana

• Use of nicotine replacement therapy, clonidine, varenicline, bupropion, or nortriptyline within the month prior to enrollment

• Use of a medication that might affect weight or appetite

• History of allergic reactions to adhesives.